KBY Biotech Indexv0.0.34
Search
← Pipeline|GIL-2445

GIL-2445

Phase 2/3
By Gilead Sciences
Source: Trial-derived·Trials: 1
Modality
Fusion Protein
MOA
ALKi
Target
PSMA
Pathway
NF-κB
PsATTR Amyloidosis
Development Pipeline
Preclinical
~Oct 2017
→ ~Jan 2019
Phase 1
~Apr 2019
→ ~Jul 2020
Phase 2
Oct 2020
Phase 2Current
NCT04647786
1,148 pts·TTR Amyloidosis
2020-10→TBD·Completed
1,148 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Trial Timeline
Q4
P2/3
Complet…
Completed|StartCompletionToday
Trials (1)
NCTPhaseIndicationStatusNEP
NCT04647786Phase 2/3TTR AmyloidosisCompleted1148DOR
Competitors (10)
DrugCompanyPhaseTargetMOA
MiriosocimabPfizerPhase 1PARPALKi
MRK-7739Merck & CoPreclinicalIL-23ALKi
AZN-3724AstraZenecaPreclinicalPSMABCMA ADC
BMY-2495Bristol-Myers SquibbPhase 3KRASG12DALKi
DoxacageneSanofiApprovedPSMASHP2i
GSK-2051GSKPhase 1PSMAEGFRi
DSN-5254Daiichi SankyoPhase 1B7-H3ALKi
SovacapivasertibAmgenPhase 3WEE1ALKi
ZanuratamabGilead SciencesPhase 1/2CDK2ALKi
BII-1564BiogenPhase 2PSMABETi